News

Prior to joining QRxPharma, Mr Soriano was senior director of business development at Osiris Therapeutics and responsible for all business development activities, including IP strategy and operations, out-licensing

Matthias M. Baltisberger, Site Head Roche Basel, commented: “The location for an investment is not chosen for sentimental reasons. So an important criterion in selecting the site for

Teva and Lonza will co-operate to develop, manufacture and market a number of affordable, efficacious and safe generic equivalents of a selected portfolio of biologic pharmaceuticals. Through this

Initially the focus will be on five of BMI’s 56 hospitals – London, Central Manchester, Birmingham, Sheffield and Harrogate. SurgiCare said that it plans to add further hospitals

The single-dose, escalating Phase I study completed in December 2008 was designed to assess DAS181 safety in healthy subjects. The study drug was well tolerated at all dose

This transaction is subject to various closing conditions, including review and approval by the Competition Bureau of Canada and the consent of Uniprix’s shareholders holding a majority of

The travelers’ diarrhea (TD) vaccine is in the form of a skin patch – a novel method for delivering a vaccine that is especially compelling because it is

The patent protects a procedure for the selective identification of improved protein variants in Austria, Belgium, Switzerland, Spain, France, the UK, Italy, Luxemburg, the Netherlands, Sweden and Germany.

The FDA indicated in its letter that they cannot approve the application for iclaprim in its current form and that additional clinical data are required to demonstrate efficacy